Showing results (141-150 of 166) with videos related to

Sort By:
Pageof 17
British Journal of Haematology|October 18, 2022
Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review studyGeorg Hess, Martin Dreyling, Lucie Oberic, et al.
Blood|October 18, 2021
High-risk subtypes of chronic lymphocytic leukemia are detectable as early as 16 years prior to diagnosisP Martijn Kolijn, Fatemeh Saberi Hosnijeh, Florentin Späth, et al.
The Lancet Regional Health. Europe|September 10, 2024
Body mass index and risk of over 100 cancer forms and subtypes in 4.1 million individuals in Sweden: the Obesity and Disease Development Sweden (ODDS) pooled cohort studyMing Sun, Marisa da Silva, Tone Bjørge, et al.
American Journal of Hematology|June 4, 2026
Development and Validation of a Novel Conditional Event-Free Survival Tool in Diffuse Large B-Cell LymphomaZhengming Chen, Danny Luan, Rasmus Rask Kragh Jørgensen, et al.
Leukemia & Lymphoma|October 16, 2023
Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphomaGeorg Hess, Martin Dreyling, Lucie Oberic, et al.
British Journal of Haematology|July 6, 2016
15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateauChristian W Eskelund, Arne Kolstad, Mats Jerkeman, et al.
Blood|March 22, 2014
Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphomaArne Kolstad, Anna Laurell, Mats Jerkeman, et al.
Blood Cancer Journal|April 24, 2025
Validation of POD24 as a robust early clinical indicator of poor survival in mantle cell lymphoma from 1280 patients on clinical trials, a LYSA studyClémentine Sarkozy, Loïc Chartier, Vincent Ribrag, et al.
Lancet (London, England)|October 6, 2025
Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2/3 superiority trialDavid J Lewis, Mats Jerkeman, Lexy Sorrell, et al.
Haematologica|September 21, 2019
KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL studySimone Ferrero, Davide Rossi, Andrea Rinaldi, et al.
Pageof 17